Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.

Phytomedicine : international journal of phytotherapy and phytopharmacology - 1 Nov 2021

Choi Miri, Kim Ae-Kyeong, Ham Youngwook, Lee Joo-Youn, Kim Daeyong, Yang Ansook, Jo Min Ju, Yoon Eunyoung, Heo Jung-Nyoung, Han Sang-Bae, Ki Min-Hyo, Lee Kyu-Sun, Cho Sungchan

Abstract excerpt

BACKGROUND: Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a significant pathogenic factor in Down syndrome (DS), wherein DYRK1A is overexpressed by 1.5-fold because of trisomy of human chromosome 21. Thus, DYRK1A inhibition is considered a therapeutic strategy to modify the disease. PURPOSE: This study aims to identify a novel DYRK1A inhibitor and validate its therapeutic potential in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Down Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Phenotype

Share to Phosphorylation

Source

Identifiers

PMID: 34500300
DOI: 10.1016/j.phymed.2021.153695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.PMID 34500300Read ↗

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's DiseaseSemantic proximity Read ↗

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read ↗

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.Semantic proximity Read ↗

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?Semantic proximity Read ↗

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directionsSemantic proximity Read ↗

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspectiveSemantic proximity Read ↗

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSemantic proximity Read ↗

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromeSemantic proximity Read ↗

An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indicationsSemantic proximity Read ↗

DYRK1A Kinase Inhibitors with Emphasis on CancerSemantic proximity Read ↗

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down SyndromeSemantic proximity Read ↗

A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replicationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.